{
  "source": "PA-Med-Nec-Brexafemme.txt",
  "chunks": [
    "UnitedHealthcare Pharmacy\nClinical Pharmacy Programs\nProgram Number 2025 P 2263-5\nProgram Prior Authorization/Medical Necessity\nMedication Brexafemme® (ibrexafungerp)\nP&T Approval Date 12/2021, 2/2022, 2/2023, 2/2024, 2/2025\nEffective Date 5/1/2025\n1. Background:\nBrexafemme (ibrexafungerp) is indicated for the treatment of adult and post-menarchal\npediatric females for the treatment of vulvovaginal candidiasis (VVC) and for the reduction\nin the incidence of recurrent vulvovaginal candidiasis (RVVC).\nCoverage will be provided for members who meet the following criteria.\n2. Coverage Criteriaa:\nA. Authorization\n1. Treatment of vulvovaginal candidiasis\na. Brexafemme will be approved based on ALL of the following criteria:\n1) Diagnosis of vulvovaginal candidiasis (VVC)\n-AND-\n2) One of the following:\na) Confirmed azole resistance demonstrated by culture and susceptibility testing\n-OR-\nb. Both of the following:\ni. Other causes (including but not limited to bacterial vaginosis or\ntrichomoniasis) have been ruled out\n-AND-\nii. Failure of a 7-day course of oral fluconazole therapy defined as 100-mg,\n150-mg, or 200-mg taken orally every third day for a total of 3 doses [days\n1, 4, and 7] for the current episode of VVC\n-AND-\n3) Prescribed by or in consultation with one of the following:\n© 2025 UnitedHealthcare Services, Inc.\n1\na) Infectious disease physician\nb) Obstetrician/Gynecologist\nAuthorization will be issued for 3 months.\n2. Recurrent vulvovaginal candidiasis\na. Brexafemme will be approved based on ALL of the following criteria:\n1) Diagnosis of recurrent vulvovaginal candidiasis (RVVC)\n-AND-\n2) One of the following:\na) Confirmed azole resistance demonstrated by culture and susceptibility testing\n-OR-\nb) Both of the following:\ni. Other causes (including but not limited to bacterial vaginosis or\ntrichomoniasis) have been ruled out\n-AND-\nii. Failure of a maintenance course of oral fluconazole defined as 100-mg,\n150-mg, or 200-mg taken weekly for 6 monthsb\n-AND-\n3) Prescribed",
    "erial vaginosis or\ntrichomoniasis) have been ruled out\n-AND-\nii. Failure of a maintenance course of oral fluconazole defined as 100-mg,\n150-mg, or 200-mg taken weekly for 6 monthsb\n-AND-\n3) Prescribed by or in consultation with one of the following:\na) Infectious disease physician\nb) Obstetrician/Gynecologist\nAuthorization will be issued for 6 months.\na State mandates may apply. Any federal regulatory requirements and the member specific benefit\nplan coverage may also impact coverage criteria. Other policies and utilization management\nprograms may apply.\nb For Connecticut, Kentucky and Mississippi business, only a 30 day trial will be required.\n3. Additional Clinical Rules:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-\nauthorization based solely on previous claim/medication history, diagnosis codes (ICD-\n10) and/or claim logic. Use of automated approval and re-approval processes varies by\nprogram and/or therapeutic class.\n© 2025 UnitedHealthcare Services, Inc.\n2\n4. References:\n1. Brexafemme [package insert]. Jersey City, NJ: Scynexis, Inc; November 2022\n2. Sexually Transmitted Infections Treatment Guidelines, 2021. Vulvovaginal Candidiasis\n(VVC). Centers for Disease Control and Prevention. https://www.cdc.gov/std/treatment-\nguidelines/candidiasis.htm. Accessed December 2023.\nProgram Prior Authorization/Medical Necessity – Brexafemme\nChange Control\n12/2021 New program\n2/2022 Removed the trial and failure language. Added that other causes of\ninfection have been ruled out.\n2/2023 Annual review. Added the new indication for recurrent vulvovaginal\ncandidiasis (RVVC).\n2/2024 Annual review. Updated mandated states.\n2/2025 Annual review. No changes.\n© 2025 UnitedHealthcare Services, Inc.\n3"
  ]
}